Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Capital Expenditures (2016 - 2025)

Bio-Techne (TECH) has 17 years of Capital Expenditures data on record, last reported at $5.9 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 13.19% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $26.3 million, down 47.84%, while the annual FY2025 figure was $31.0 million, 50.69% down from the prior year.
  • Capital Expenditures reached $5.9 million in Q4 2025 per TECH's latest filing, up from $5.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $18.0 million in Q2 2024 and bottomed at $4.9 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $10.5 million, with a median of $10.4 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 143.31% in 2023, then tumbled 72.8% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $10.2 million in 2021, then tumbled by 39.92% to $6.1 million in 2022, then surged by 143.31% to $14.9 million in 2023, then plummeted by 54.11% to $6.8 million in 2024, then fell by 13.19% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $5.9 million in Q4 2025, $5.4 million in Q3 2025, and $4.9 million in Q2 2025.